Overview

A Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of the Combination of Ibrutinib With Nivolumab in Participants With Hematologic Malignancies

Status:
Active, not recruiting

Trial end date:
2022-03-31

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine the safety and to establish the recommended phase 2 dose (RP2D) for the combination of ibrutinib and nivolumab in participants with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), follicular cell lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL). Once the dose is optimized, the combination will be assessed for Pharmacokinetics, Pharmacodynamics, and preliminary efficacy, further safety in participants with CLL/SLL, FL or DLBCL and in participants with Richter syndrome.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Janssen Research & Development, LLC

Collaborators:

Bristol Meyers Squibb (BMS)
Bristol-Myers Squibb

Treatments:

Antibodies, Monoclonal
Nivolumab